Hoess brings more than 17 years of experience in business development, strategic planning and commercialisation in the biotechnology sector to the Heidelberg-based company. He was previously chief executive of Berlin-based Jenowis. Prior to 2009 he was with Jerini, where he was chief commercial officer and responsible for the product launch of Firazyr and business development.
During his professional career, Hoess has been vice president and general manager of the Molecular Medical Division at Carl Zeiss Jena. He also held senior management positions in business development at MorphoSys, most recently as vice president licensing/business development.
Hoess said: ‘The TandAb platform and the derived products provide very promising potential that will enable Affimed to become a leading player in bispecific antibodies. Initially, I will focus on one major goal: partnerships with the pharmaceutical industry for our products and platform.’
